Home Alzheimer’s Disease Margetuximab Plus Chemo Improves PFS Versus Trastuzumab/Chemo in ERBB2+ Advanced Breast Cancer

Margetuximab Plus Chemo Improves PFS Versus Trastuzumab/Chemo in ERBB2+ Advanced Breast Cancer

Results from the randomized, open-label, phase 3 SOPHIA trial (NCT02492711) suggest that among patients with pretreated ERBB2-positive advanced breast cancer, a disease that is typically incurable, margetuximab (Margenza) plus chemotherapy resulted in a statistically significant improvement in progression-free survival (PFS) compared with trastuzumab (Herceptin) plus chemotherapy following progression on 2 or more prior anti-ERBB2 therapies.1

The study, published in JAMA Oncology, also indicated that margetuximab plus chemotherapy had an acceptable safety profile which was comparable to that observed with trastuzumab plus chemotherapy.

“Alternatives for this patient population include neratinib [Nerlynx], tucatinib [Tukysa], and trastuzumab deruxtecan [Enhertu], which have emerged as active regimens, albeit with different levels of effectiveness, and all with notable toxic…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments